Literature DB >> 16641396

Vitamins C and E and the risks of preeclampsia and perinatal complications.

Alice R Rumbold1, Caroline A Crowther, Ross R Haslam, Gustaaf A Dekker, Jeffrey S Robinson.   

Abstract

BACKGROUND: Supplementation with antioxidant vitamins has been proposed to reduce the risk of preeclampsia and perinatal complications, but the effects of this intervention are uncertain.
METHODS: We conducted a multicenter, randomized trial of nulliparous women between 14 and 22 weeks of gestation. Women were assigned to daily supplementation with 1000 mg of vitamin C and 400 IU of vitamin E or placebo (microcrystalline cellulose) until delivery. Primary outcomes were the risks of maternal preeclampsia, death or serious outcomes in the infants (on the basis of definitions used by the Australian and New Zealand Neonatal Network), and delivering an infant whose birth weight was below the 10th percentile for gestational age.
RESULTS: Of the 1877 women enrolled in the study, 935 were randomly assigned to the vitamin group and 942 to the placebo group. Baseline characteristics of the two groups were similar. There were no significant differences between the vitamin and placebo groups in the risk of preeclampsia (6.0 percent and 5.0 percent, respectively; relative risk, 1.20; 95 percent confidence interval, 0.82 to 1.75), death or serious outcomes in the infant (9.5 percent and 12.1 percent; relative risk, 0.79; 95 percent confidence interval, 0.61 to 1.02), or having an infant with a birth weight below the 10th percentile for gestational age (8.7 percent and 9.9 percent; relative risk, 0.87; 95 percent confidence interval, 0.66 to 1.16).
CONCLUSIONS: Supplementation with vitamins C and E during pregnancy does not reduce the risk of preeclampsia in nulliparous women, the risk of intrauterine growth restriction, or the risk of death or other serious outcomes in their infants. (Controlledtrials.com number, ISRCTN00416244.). Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641396     DOI: 10.1056/NEJMoa054186

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  109 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

2.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

3.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

4.  Role of reactive oxygen species during hypertension in response to chronic antiangiogenic factor (sFlt-1) excess in pregnant rats.

Authors:  Kiran B Tam Tam; Babbette Lamarca; Marietta Arany; Kathy Cockrell; Lillian Fournier; Sydney Murphy; James N Martin; Joey P Granger
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

5.  Plasma vitamin C concentration in pregnant women with pre-eclampsia in Mulago hospital, Kampala, Uganda.

Authors:  P Kiondo; G Welishe; J Wandabwa; G Wamuyu-Maina; G S Bimenya; P Okong
Journal:  Afr Health Sci       Date:  2011-12       Impact factor: 0.927

Review 6.  Stillbirth in the pregnancy complicated by diabetes.

Authors:  Roman Starikov; Donald Dudley; Uma M Reddy
Journal:  Curr Diab Rep       Date:  2015-03       Impact factor: 4.810

Review 7.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 8.  Preeclampsia and diabetes.

Authors:  Tracey L Weissgerber; Lanay M Mudd
Journal:  Curr Diab Rep       Date:  2015-03       Impact factor: 4.810

9.  New Insights into the Pathogenesis of Preeclampsia - The Role of Nrf2 Activators and their Potential Therapeutic Impact.

Authors:  N Kweider; C J Wruck; W Rath
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

10.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.